Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic

  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

4.850 -0.060 (-1.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutic Com

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Sage Therapeutics: Q1 Earnings Insights
Sage Therapeutics (NASDAQ:SAGE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
Expert Ratings For Sage Therapeutics
Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter. 
Via Benzinga
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
Sage Therapeutics (NASDAQ:SAGE) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
From Sage Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, investor! It's the last trading day of the week and that means it's time to get into the pre-market stock movers for Friday! 
Via InvestorPlace
Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 LUMINARY Study of SAGE-718 in Patients with Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
Upgrades 
Via Benzinga
Sage Therapeutics to Present at 2022 Stifel CNS Days
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
Expert Ratings For Sage Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
Sage Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Why A Biogen-Sage Drug Flopped — And Could Still Be Approved
The companies tested a combination of zuranolone and depression drugs. 
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company... 
Via Benzinga
56 Biggest Movers From Yesterday
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) gained 54.5% to close at $2.07 on Wednesday. Hookipa Pharma amended and restated collaboration and license agreement with Gilead... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) jumped 52.8% to $2.0478. Hookipa Pharma amended and restated collaboration and license agreement with Gilead Sciences for arenaviral... 
Via Benzinga
Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) said zuranolone combined with a standard of care antidepressant met the primary goal of showing... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
From Sage Therapeutics, Inc.
Via Business Wire
New Psychedelics ETF Launches On NYSE Arca
Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)... 
Via Benzinga
Sage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
From Sage Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.